<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00906841</url>
  </required_header>
  <id_info>
    <org_study_id>RIT90Y-DOTA-hLL2</org_study_id>
    <nct_id>NCT00906841</nct_id>
  </id_info>
  <brief_title>Study of 90Y-DOTA-hLL2 as a Consolidation Therapy After R-CHOP in Patients With Diffuse Large B-cell Lymphoma</brief_title>
  <official_title>Phase II Study of Evaluation of Fractionated Radio-immunotherapy With 90Y-DOTA-hLL2 as a Consolidation Therapy After First Line of Chemotherapy in Patients Older Than 60 With Disseminated Diffuse Large B-cell Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>French Innovative Leukemia Organisation</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>French Innovative Leukemia Organisation</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Phase II, multi-centric, open-label, study.&#xD;
&#xD;
      Disseminated diffuse large B-cell lymphoma in patients older than 60: evaluation of&#xD;
      fractionated radio-immunotherapy with 90Y-DOTA-hLL2 as a consolidation therapy after first&#xD;
      line of chemotherapy.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Initial treatment: 6 courses of CHOP-R 14 with evaluation of response before C4 (observation&#xD;
      of no change or progression at this time will get the patient off study).&#xD;
&#xD;
      Consolidation : fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2&#xD;
      of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    completed recruitment of patients on 15 december 2010&#xD;
  </why_stopped>
  <start_date>October 2007</start_date>
  <completion_date type="Actual">April 2018</completion_date>
  <primary_completion_date type="Actual">March 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Event free survival (EFS)</measure>
    <time_frame>EFS post treatment (at 2 years)</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Objective disease response (CR, CRu and PR), SD and disease progression</measure>
    <time_frame>OS after treatment</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Duration of response</measure>
    <time_frame>Time interval from the date on which a response (CR, CRu and PR)</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Time to disease progression</measure>
    <time_frame>Time interval from the date from initial of study treatment until the date on which disease progression is documented</time_frame>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">75</enrollment>
  <condition>B-cell Lymphoma</condition>
  <arm_group>
    <arm_group_label>90Y-DOTA-hLL2</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>90Y-DOTA-hLL2</intervention_name>
    <description>Consolidation : Fractionated RIT (8 weeks after the end of R-CHOP: 2 injections of 15 mCi/m2 of 90Y-DOTA-hLL2 and hLL2 at day 1 and day 8)</description>
    <arm_group_label>90Y-DOTA-hLL2</arm_group_label>
    <other_name>consolidation</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age &gt; 60 and &lt; 80 years&#xD;
&#xD;
          -  Non eligible for stem cell transplantation&#xD;
&#xD;
          -  CD20 diffuse large B-cell lymphoma according to the WHO classification&#xD;
&#xD;
          -  Bulky stage I and II &gt; ou =7 cm and stage III and IV&#xD;
&#xD;
          -  Performance status 0 - 2&#xD;
&#xD;
          -  Creatinine clearance &gt;ou = 50 ml/min (Cockroft formula).&#xD;
&#xD;
          -  Serum bilirubin &lt; ou =30 mmol/l&#xD;
&#xD;
          -  Leucocytes &gt; ou =3 G/l, granulocytes &gt; ou = 1,5 G/l, platelets &gt;ou= 100 G/L.&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
          -  Written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age &lt; 60 years and &gt; 80 years&#xD;
&#xD;
          -  Other types of lymphomas except CD20+ diffuse large B-cell lymphoma according to the&#xD;
             WHO classification&#xD;
&#xD;
          -  Histologic transformation of low grade lymphoma (Involvement of the bone marrow by&#xD;
             small B-cell lymphoma will not lead to exclusion of the patient)&#xD;
&#xD;
          -  Primary lymphoma of the central nervous system and transformed gastro intestinal MALT&#xD;
             lymphoma&#xD;
&#xD;
          -  Meningeal involvement&#xD;
&#xD;
          -  Bone marrow involvement &gt; 25% after R-CHOP&#xD;
&#xD;
          -  Aggressive post-transplantation lymphoma&#xD;
&#xD;
          -  Absence of CD20 expression on tumor cells&#xD;
&#xD;
          -  Non bulky stages I et II&#xD;
&#xD;
          -  HIV positive&#xD;
&#xD;
          -  Active Hepatitis B or C&#xD;
&#xD;
          -  Left ventricular ejection fraction &lt; 50%.&#xD;
&#xD;
          -  Contra-indication to R-CHOP treatment&#xD;
&#xD;
          -  Previous or concurrent second malignancy except for adequately treated basal cell&#xD;
             carcinoma of the skin, curatively treated in situ carcinoma of the cervix, curatively&#xD;
             treated solid cancer, with no evidence of disease for at least 5 years&#xD;
&#xD;
          -  Any psychological, familial, sociological or geographical condition potentially&#xD;
             hampering compliance with the study protocol and follow-up schedule&#xD;
&#xD;
          -  Participation at the same time in another study in which investigational drugs are&#xD;
             used&#xD;
&#xD;
          -  Absence of written informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>60 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Fran√ßoise KRAEBER BODERE, MDPD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Pierre SOUBEYRAN, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>French Innovative Leukemia Organisation</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Chu/Clcc Nantes</name>
      <address>
        <city>Nantes</city>
        <zip>44093</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <link>
    <url>http://www.filo-leucemie.org</url>
    <description>FILO Internet site</description>
  </link>
  <verification_date>April 2018</verification_date>
  <study_first_submitted>May 18, 2009</study_first_submitted>
  <study_first_submitted_qc>May 20, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 21, 2009</study_first_posted>
  <last_update_submitted>April 26, 2018</last_update_submitted>
  <last_update_submitted_qc>April 26, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">April 27, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Disseminated diffuse large B-cell lymphoma</keyword>
  <keyword>first line treatment</keyword>
  <keyword>R CHOP</keyword>
  <keyword>90Y-DOTA-hLL2</keyword>
  <keyword>Patients older than 60 years</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
    <mesh_term>Lymphoma, B-Cell</mesh_term>
    <mesh_term>Lymphoma, Large B-Cell, Diffuse</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

